Cortagen vs Vilon: do you need both peptides

Cortagen and Vilon are both Khavinson-family bioregulator peptides, but they were built to do completely different jobs. Cortagen targets cortical neurons and is sold as a cognitive peptide. Vilon targets thymic immune cells and is sold as an immune and longevity peptide. Short answer: you need Cortagen if your goal is cognitive recovery or slow-onset nootropic support, you need Vilon if your goal is immune function and general longevity signaling, and you need both only if you are actually chasing both outcomes at once, since neither one substitutes for the other's mechanism.

I get this question a lot from people who found both peptides in the same forum thread and assumed they were interchangeable options from the same catalog, like picking between two brands of the same supplement. They are not. They come from the same Soviet-era research program out of the Military Medical Academy in Leningrad, and they share the same theoretical mechanism, short peptides crossing into the cell nucleus and binding DNA promoter regions to modulate gene expression in a tissue-specific way. But "tissue-specific" is the operative phrase. Cortagen's target tissue is cortical neurons. Vilon's is thymic and lymphocyte tissue. Running one does nothing for what the other is built to do.

Evidence quality: where each one actually stands

Vilon has the deeper human data set of the two, and it is worth being specific rather than vague about it. There's a Russian cohort of elderly diabetics that saw improved coagulation and immune markers along with reduced insulin requirements, another showing reduced clotting complications in type-1 diabetes, and a case series in elderly stage-III colorectal cancer patients that found better survival and fewer complications. None of these are large randomized trials by Western standards, they're small Russian cohort and case-series work, but they are human data, and there's a consistent thread across them of immune and metabolic markers moving in the right direction in older, sicker populations.

Cortagen's human evidence sits on unblinded Russian post-stroke recovery studies, which show cognitive improvement but lack the blinded design a Western reviewer would want before calling it proof. Underneath that, both peptides have supporting in-vitro work. For Vilon, chromatin studies show it drives selective heterochromatin decondensation and gene reactivation in aging cells, and more recent work found it increased SIRT1 and decreased PARP1/PARP2 expression in aging human mesenchymal stem cells, which is a real longevity-adjacent signal even though it came from cultured cells in a dish rather than a living person. Cortagen's supporting data is animal work, Morris water maze performance and hippocampal BDNF changes in rodents. Neither peptide has a Western randomized controlled trial. If you're ranking the two purely on evidence depth, Vilon comes out ahead on human data, Cortagen comes out ahead on mechanistic plausibility for its specific cognitive claim.

Cost, sourcing, and the counterfeit problem

Here's where I'd actually slow you down before you buy either one. Vilon has the same sourcing problem. Khavinson-family peptides as a group are the most counterfeited category I see in this space, more than BPC-157 or TB-500, because the buyer pool is smaller and more forum-dependent, which means less market pressure pushing vendors toward third-party testing. Whatever you pay for either compound, a certificate of analysis confirming identity and purity above 99% is not optional. I've seen people run a "Vilon" that was mislabeled filler and conclude the peptide doesn't work, when the real problem was the vial they bought.

Heads up: OHM has an affiliate relationship with the vendors linked on this site, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence actually supports, and in this case neither Cortagen nor Vilon has a verified vendor I can point you to yet, so treat any seller offering either one with more scrutiny than you would a mainstream peptide.

Side-effect load and who each one actually suits

Both peptides report a similarly mild adverse-event profile in the Russian literature: occasional injection-site reactions, transient mild headache early in a cycle, nothing serious documented at standard doses. Neither has long-term repeated-cycle safety data in Western pharmacovigilance systems, so "mild so far" comes with the caveat that nobody has tracked people running these for a decade.

Who actually needs Cortagen: someone specifically chasing cognitive recovery, particularly post-injury or post-stroke recovery support, who has already looked at faster-acting options like Semax or Selank and wants the slower, cycle-based approach instead. Cortagen is built around a 10 to 20 day cycle with effects claimed to persist two to three months afterward, so it suits someone willing to commit to a pulse-and-rest schedule rather than daily dosing.

Who actually needs Vilon: someone specifically interested in immune-system support and longevity signaling in an aging-focused stack, who understands they're working from a Russian cohort and in-vitro evidence base rather than a Western trial. If your actual goal is thymic immune support, I'd also point you toward Thymosin alpha-1, which has a stronger Western trial record and is easier to source with a verified COA. Vilon still has a place if you're specifically drawn to the Khavinson-school longevity mechanism, the SIRT1 and chromatin work, rather than immune function alone.

Now the part my lawyer makes me say, and he's right: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Community protocols for both compounds converge on a similar shape: subcutaneous dosing in the 100 to 400 mcg range depending on the peptide and context, run over a 10 to 20 day cycle, repeated two to three times a year rather than continuously. That cycling philosophy is shared across the whole Khavinson family, including Pinealon and Epithalon, and it's built around the claim that gene-expression effects outlast the dosing window, which is a hypothesis that hasn't been independently confirmed yet.

If you're deciding between the two, ask what problem you're actually solving. A cognitive recovery goal points to Cortagen. An immune or longevity goal points to Vilon, with the caveat that Thymosin alpha-1 may serve the immune goal better. Running both only makes sense if you genuinely have both goals, since paying for two under-sourced, thinly-tested peptides to chase one outcome is money spent for no additional benefit.